Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE:MTEC; Frankfurt:3CM), a leading business technology company in the cannabis space, is pleased to announce the appointment of Shirish Patel, MD to its Health and Innovation Advisory Board. The Health and Innovation Advisory Board oversees all content related to the Cannvas.me platform, a scalable solution for the global medical cannabis community offering interactive tools, educational modules and physician-backed content to audiences wishing to learn about healthcare through cannabis.

“I am delighted to join Cannvas’ Health and Innovation Advisory Board in an effort to continue to bring the health and wellness benefits of cannabis to patients in Canada and around the world,” said Shirish Patel, MD. “As a medical advisor for a concierge medical cannabis clinic in Toronto, I witness the benefits of medical cannabis on a regular basis. I also strongly believe that technology can play an important role in the delivery and education of medical cannabis leading improved patient outcomes. The Cannvas.me online platform will have global reach and be able to provide patients and doctors with knowledge and education on an international basis. I look forward to working with the Cannvas team on this important project.”


“We are honoured to have Dr. Patel join our Health and Innovation Advisory Board as we prepare to launch Cannvas.me, our solution to medical cannabis information and education,” said Shawn Moniz, Chief Executive Officer, Cannvas MedTech Inc. “Dr. Patel is a highly respected and accomplished medical doctor and researcher with considerable experience with leveraging technology to improve the healthcare system in Canada and the United States. He is a valuable addition to the advisory board and I look forward to collaborating with Dr. Patel to bring advanced technology to the medical cannabis space.”

Dr. Patel is an engineer-turned-clinician with a passion for neurology, psychiatry, immunology, pharmacology, pharmacogenomics, and electronic healthcare delivery. For the past three years he has been working as a Neuropsychiatric Intake Specialist and Counselor for a private psychosomatic psychiatry clinic located in Toronto, Ontario. He also works as the medical advisor for My Natural Living Life, a concierge medical cannabis clinic and most recently took on a concurrent role as the Medical Advisor for health informatics & measurement-based care with Trendlines Health Inc., a company specializing in remote data acquisition from wearable health devices for data consolidation and analysis.

Dr. Patel strengths lie in the scientific exchange and translation from clinical research to help support health care providers with clinical decision making skills. As a skilled researcher he is authoring and co-authoring several articles for publications covering topics including mobile mental health technology, neurobiology, and neurodevelopmental disorders. In 2018, Dr. Patel has presented a total of five scientific posters at the American Psychiatric Association (APA) annual meeting, developed in collaboration with leading psychiatrists and psychiatry residents from Canada and the U.S.

Cannvas.me is a scalable and comprehensive solution for the global medical cannabis community offering interactive tools and physician-backed content to audiences wishing to learn about healthcare through cannabis. Its Cannvas Academy, already guided by its Medical Advisory Board, will receive additional oversight and direction from the Education Advisory Panel, made up of highly qualified members from industry and government institutions.

About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

SOURCE Cannvas MedTech Inc.

For further information: www.cannvasmedtech.com; Media Inquiries, media@cannvasmedtech.com; Investor Relations, ir@cannvasmedtech.com, 1-800-489-0116

Source: www.newswire.ca

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less